V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160012898 | 160006238 | 1.77 | 90 | null | 2018-09-25 | 2018-10-26 | Liposomal Doxorubicin (Caelyx) | 2 | N | TRABECTEDIN | 101743408 |
| 160012899 | 160006239 | null | 34.1 | null | 2016-08-29 | 2016-09-06 | Liposomal Doxorubicin (Caelyx) | 02 | null | DOXORUBICIN + IFOSFAMIDE | 101491203 |
| 160012900 | 160006240 | 0 | 31.1 | Palliative (P) | null | 2017-01-17 | Cisplatin + Pemetrexed | 02 | Y | CISPLATIN + PEMETREXED | 101816000 |
| 160012902 | 160006241 | 1.78 | 77.5 | Palliative (P) | 2005-02-18 | 2016-12-27 | DOXORUBICIN | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100065320 |
| 160012908 | 160006242 | 1.78 | 85.1 | null | 2017-11-18 | 2017-11-27 | Liposomal Doxorubicin (Caelyx) | 02 | null | DOXORUBICIN + ETOPOSIDE + IFOSFAMIDE + VINCRISTINE | 101684288 |
| 160012909 | 160006243 | 1.71 | 101 | Palliative (P) | 2018-06-09 | 2018-06-30 | DOXORUBICIN | 02 | N | CARBOPLATIN + GEMCITABINE | 100374174 |
| 160012910 | 160006244 | 1.72 | 72 | Palliative (P) | 2019-01-09 | 2019-01-10 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101340979 |
| 160012912 | 160006245 | 1.58 | 74 | Palliative (P) | 2018-02-21 | 2018-03-01 | Doxorubicin + Ifosfamide | 01 | N | ATOMIC-MESO TRIAL | 100371096 |
| 160012914 | 160006246 | null | 64.8 | Palliative (P) | 2016-06-14 | 2016-06-17 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 100701225 |
| 160012915 | 160006247 | 1.66 | 24.4 | Palliative (P) | 2017-10-13 | 2017-10-16 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 101136073 |
| 160012917 | 160006248 | 1.95 | 61.2 | Palliative (P) | 2016-10-21 | 2016-10-24 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101206477 |
| 160012919 | 160006249 | 1.71 | 86.4 | Palliative (P) | 2018-10-28 | 2018-10-30 | null | 02 | N | STS RHABDOMYOSARCO RMS 2005 IVADOVV | 101123649 |
| 160012920 | 160006250 | 1.76 | 70.6 | 03 | 2016-04-05 | 2016-05-11 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | IVA | 101021910 |
| 160012921 | 160006251 | 1.54 | 88.6 | Palliative (P) | 2021-02-18 | 2021-02-19 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100784995 |
| 160012922 | 160006252 | 1.88 | 77.1 | null | 2021-08-27 | 2021-09-03 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100163281 |
| 160012925 | 160006253 | 1.79 | 58.2 | Curative (C) | 2019-09-30 | 2019-10-09 | Cisplatin + Pemetrexed | 01 | N | CISPLATIN + PEMETREXED | 100526711 |
| 160012927 | 160006254 | 1.62 | 62.3 | Palliative (P) | 2017-11-17 | 2017-12-03 | CARBOPLATIN + PACLITAXEL | N | N | CARBOPLATIN + PACLITAXEL | 100064513 |
| 160012929 | 160006255 | 1.58 | 53.3 | Palliative (P) | 2020-07-18 | 2020-07-21 | Cisplatin + Pemetrexed | 02 | null | BEVACIZUMAB + CARBO + PACLITAXEL | 100243657 |
| 160012930 | 160006256 | 1.82 | 20.8 | Palliative (P) | 2019-11-02 | 2019-11-05 | Bevacizumab 7.5mg/kg | 02 | Y | EW EUROEWING 2012 ARM B VDC | 101548479 |
| 160012932 | 160006257 | 0 | 0 | Curative (C) | 2018-04-06 | 2018-04-07 | CARBOPLATIN + PACLITAXEL | 02 | N | CARBOPLATIN + PACLITAXEL | 101154151 |
| 160012933 | 160006258 | 1.68 | 83.3 | Neo-adjuvant (N) | 2019-12-10 | 2019-12-12 | Doxorubicin + Ifosfamide | 02 | N | TRABECTEDIN | 101799509 |
| 160012934 | 160006259 | 1.74 | 100 | Neo-adjuvant (N) | 2017-11-27 | 2017-12-13 | BEVACIZUMAB + CARBO + PACLITAXEL | n | N | DOXORUBICIN + OLARATUMAB | 101586702 |
| 160012935 | 160006260 | 0.02 | 80.4 | Neo-adjuvant (N) | 2018-10-23 | 2018-10-25 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100915244 |
| 160012936 | 160006261 | 1.64 | 109 | Neo-adjuvant (N) | null | null | EpSSG NRSTS 2005 | 02 | N | ATOMIC-MESO TRIAL | 101727795 |
| 160012937 | 160006262 | 1.5 | 89.2 | Palliative (P) | 2016-09-23 | 2016-09-27 | PACLITAXEL | 02 | N | NB HRNBL-1 COJEC IND COURSE A | 100070628 |
| 160012938 | 160006263 | 1.95 | 67.6 | null | 2019-04-27 | 2019-05-04 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 101347946 |
| 160012939 | 160006264 | 1.64 | 44 | 03 | 2019-02-02 | 2019-02-08 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101728630 |
| 160012940 | 160006265 | 1.58 | 81.75 | Curative (C) | 2018-08-14 | 2018-08-28 | Doxorubicin + Olaratumab | 02 | N | STS NON-RHABDO EPSSG 2005 VDCY | 101123079 |
| 160012941 | 160006266 | 1.78 | 72 | Neo-adjuvant (N) | 2018-03-26 | 2018-04-21 | Carboplatin AUC 2 - 5 | 02 | N | DOXORUBICIN | 101853424 |
| 160012942 | 160006267 | 1.91 | 76.6 | Neo-adjuvant (N) | 2018-05-15 | 2018-05-15 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101833970 |
| 160012946 | 160006268 | 1.66 | 51.8 | Palliative (P) | 2017-03-27 | 2017-04-03 | Trial Unspecified | 02 | null | TRIAL | 100973299 |
| 160012947 | 160006269 | 1.56 | 57.5 | Palliative (P) | 2018-04-16 | 2018-04-25 | Cisplatin + Pemetrexed | 02 | N | TRIAL | 100117873 |
| 160012948 | 160006270 | 1.86 | 62 | Curative (C) | 2018-06-18 | 2018-06-18 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100251999 |
| 160012949 | 160006271 | 1.51 | 91.75 | Palliative (P) | 2019-07-09 | 2019-07-09 | Bevacizumab | 02 | N | DACTINOMYCIN + IFOSFAMIDE + VINCRISTINE | 101086846 |
| 160012950 | 160006272 | 1.72 | 69.1 | null | 2017-08-28 | 2017-10-09 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101450739 |
| 160012953 | 160006273 | 0 | 0 | Neo-adjuvant (N) | 2016-12-22 | 2016-12-31 | DOCETAXEL + GEMCITABINE | null | N | ECF | 100372673 |
| 160012956 | 160006274 | 1.78 | 92.1 | null | null | 2017-06-07 | BEVACIZUMAB + CARBO + PACLITAXEL | 02 | null | STS RHABDO RMS 2005 VIN CYCLO | 101811478 |
| 160012960 | 160006275 | 1.65 | 68.4 | Neo-adjuvant (N) | 2018-08-17 | 2018-08-19 | Vinblastine | 02 | N | VIDE | 101236381 |
| 160012961 | 160006276 | 0 | 0 | Curative (C) | 2019-12-10 | 2019-12-10 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101372013 |
| 160012962 | 160006277 | 1.68 | 99.4 | null | 2022-02-19 | 2022-02-19 | Cisplatin + Doxorubicin | 02 | N | MELPHALAN | 100195645 |
| 160012963 | 160006278 | 1.68 | 72.2 | Palliative (P) | 2019-03-13 | 2019-03-13 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100483159 |
| 160012964 | 160006279 | 1.62 | 73 | Palliative (P) | 2019-12-22 | 2019-12-22 | Cisplatin + Doxorubicin | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100851834 |
| 160012966 | 160006280 | 1.9 | 12.8 | null | 2017-01-15 | 2017-01-30 | Docetaxel + Gemcitabine with GCSF | 02 | N | DOXORUBICIN | 101828394 |
| 160012969 | 160006281 | 1.78 | 73 | null | 2019-10-04 | 2019-10-15 | Trial Unspecified | 2 | null | TRIAL UNSPECIFIED | 100337496 |
| 160012971 | 160006282 | 1.77 | 86.9 | Neo-adjuvant (N) | 2018-12-01 | 2018-12-26 | null | 02 | N | CETUXIMAB + IRINOTECAN + MDG | 101093513 |
| 160012972 | 160006283 | 1.65 | 90.1 | null | 2013-10-27 | 2013-11-12 | IVADo | 02 | N | DOXORUBICIN + OLARATUMAB | 101172326 |
| 160012974 | 160006284 | 1.86 | 53.6 | Palliative (P) | 2017-07-04 | 2017-07-04 | Pemetrexed | 02 | N | DOXORUBICIN + OLARATUMAB | 101526027 |
| 160012975 | 160006285 | 1.6 | 64.2 | null | 2018-04-03 | 2018-04-13 | VAC | 02 | null | TRIAL UNSPECIFIED | 100109967 |
| 160012976 | 160006286 | 1.75 | 61 | Palliative (P) | 2017-09-05 | 2017-09-11 | Imatinib 400mg | 99 | N | NOT MATCHED | 100977772 |
| 160012978 | 160006287 | 1.8 | 81.5 | Palliative (P) | 2016-08-09 | 2016-08-16 | null | null | null | LIPOSOMAL DOXORUBICIN | 101198453 |